Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

External reorganization energy, λext, is of paramount importance in condensed-phase electron transfer (ET) processes, but its precise determination remains a challenge. We here combine classical ...